EP0595890A1 - Antimicrobial treatment methods and compositions - Google Patents
Antimicrobial treatment methods and compositionsInfo
- Publication number
- EP0595890A1 EP0595890A1 EP92915528A EP92915528A EP0595890A1 EP 0595890 A1 EP0595890 A1 EP 0595890A1 EP 92915528 A EP92915528 A EP 92915528A EP 92915528 A EP92915528 A EP 92915528A EP 0595890 A1 EP0595890 A1 EP 0595890A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bismuth subsalicylate
- antimicrobial
- treatment
- safe
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000011282 treatment Methods 0.000 title claims description 39
- 239000000203 mixture Substances 0.000 title claims description 31
- 208000015181 infectious disease Diseases 0.000 claims abstract description 64
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 claims abstract description 63
- 229960000782 bismuth subsalicylate Drugs 0.000 claims abstract description 63
- 239000004599 antimicrobial Substances 0.000 claims abstract description 54
- 241000193163 Clostridioides difficile Species 0.000 claims abstract description 16
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 229960000282 metronidazole Drugs 0.000 claims description 10
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 10
- 229930182555 Penicillin Natural products 0.000 claims description 9
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 8
- 229960005053 tinidazole Drugs 0.000 claims description 8
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 6
- 239000004098 Tetracycline Substances 0.000 claims description 6
- 229960003022 amoxicillin Drugs 0.000 claims description 6
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 6
- 229960003722 doxycycline Drugs 0.000 claims description 6
- 229960003276 erythromycin Drugs 0.000 claims description 6
- 229960000564 nitrofurantoin Drugs 0.000 claims description 6
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 claims description 6
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000019364 tetracycline Nutrition 0.000 claims description 6
- 150000003522 tetracyclines Chemical class 0.000 claims description 6
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 claims description 5
- 229940126575 aminoglycoside Drugs 0.000 claims description 5
- 229960000723 ampicillin Drugs 0.000 claims description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 5
- 229960005361 cefaclor Drugs 0.000 claims description 5
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 5
- 229960003405 ciprofloxacin Drugs 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 5
- 229940041033 macrolides Drugs 0.000 claims description 5
- 150000002960 penicillins Chemical class 0.000 claims description 5
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims description 5
- 229930186147 Cephalosporin Natural products 0.000 claims description 4
- 229940124587 cephalosporin Drugs 0.000 claims description 4
- 150000001780 cephalosporins Chemical class 0.000 claims description 4
- 229960005091 chloramphenicol Drugs 0.000 claims description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 4
- 229960002227 clindamycin Drugs 0.000 claims description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 4
- 229960004918 nimorazole Drugs 0.000 claims description 4
- MDJFHRLTPRPZLY-UHFFFAOYSA-N nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 claims description 4
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 4
- 229960001180 norfloxacin Drugs 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 229940040944 tetracyclines Drugs 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 3
- 229940124307 fluoroquinolone Drugs 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 150000003456 sulfonamides Chemical class 0.000 claims description 3
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 2
- 206010048038 Wound infection Diseases 0.000 claims description 2
- 229910052797 bismuth Inorganic materials 0.000 claims description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 2
- -1 clinda¬ mycin Chemical compound 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 7
- 230000000474 nursing effect Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 6
- 238000011269 treatment regimen Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229940101070 pepto-bismol Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000037384 Clostridium Infections Diseases 0.000 description 3
- 206010054236 Clostridium difficile infection Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011203 antimicrobial therapy Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000001374 post-anti-biotic effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 150000002085 enols Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000031650 Surgical Wound Infection Diseases 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012092 latex agglutination test Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 201000010434 protein-losing enteropathy Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the present invention relates to a method for treating patients having infections with antimicrobials when the patients are at risk to Clostridium difficile ("L. difficile", infection.
- This method comprises concurrently orally administering before the end of about 5 days of antimicrobial therapy a safe and effective amount of bismuth subsalicylate.
- the present invention also relates to compositions useful for the method of the present invention comprising certain antimicrobials and bismuth subsalicylate.
- Bismuth subsalicylate has been investigated for its effectiveness in treating C_j. difficile colitis in hamsters [Chang et al., "Effect of Bismuth Subsalicylate on Clostridium difficile Colitis in Hamsters", Rev. Infect. Pis.. 12 (Supplement 1), pages S57-S58 (1990)]. Further, bismuth subsalicylate has been used to treat (______ difficile diarrhea in nursing homes (Bennett et al., Geriatrics, supra) and chronic diarrhea due to C difficile in children (Gryboski et al., "Effect of bismuth subsalicylate on chronic diarrhea in childhood: a preliminary report", Rev. Infect. Pis.. ⁇ 2 (Supplement 1), pages S36-S40 (1990)].
- an object of the present invention is to provide compositions and methods for treating patients at risk to Cj. difficile infection with antimicrobials.
- a further objective is to improve the chances of successful completion of an antimicrobial treatment regimen in patients at risk to C ⁇ . difficile infection.
- a further object is to reduce the mortality rate for patients being treated with antimicrobials who are at risk to ______ difficile infection.
- the present invention relates to a method for treating with antimicrobials patients at risk to £__. difficile infection, said method comprising administering to a patient at risk to £__. difficile infection who needs antimicrobial treatment for infection a safe and effective amount of an antimicrobial agent and concurrently orally administering before the end of about 5 days of antimicrobial treatment a safe and effective amount of bismuth subsalicylate.
- the present invention also relates to oral antimicrobial compositions useful for treating patients at risk to Z difficile infection comprising: (a) an orally administrable antimicrobial agent in an amount safe and effective for treating infections other than infections of the upper gastrointestinal tract; (b) a safe and effective amount of bismuth subsalicylate; and (c) pharmaceutically-acceptable carrier material suitable for oral administration.
- the present invention relates to a method for treating with antimicrobials patients at risk to £__. difficile infection who need antimicrobial treatment for infection.
- This method comprises administering to such patients a safe and effective amount of an antimicrobial agent and concurrently orally administering before the end of about 5 days of antimicrobial treatment a safe and effective amount of bismuth subsalicylate.
- the present invention methods are useful for treating with antimicrobial agents infections of humans. Such infections are typically other than infections of the upper gastrointestinal tract (e.g., Helicobacter pylori, a.k.a. Campy!obacter pyloridis.
- infections treatable according to the present invention include, but are not limited to, upper and lower respiratory tract infections, sepsis, and wound infections including surgical wound infections.
- patient at risk to C ⁇ . difficile infection means a human subject in need of antimicrobial treatment for infection and this subject is either infected with £__. difficile or deemed to be at risk to becoming infected with C difficile within the scope of sound medical judgment.
- Patients at risk to £__. difficile infection therefore include patients already diagnosed as being colonized by C__. difficile (but preferably not exhibiting £___ difficile diarrhea), as well as those patients in an environment wherein C ⁇ difficile infection is known to be present or is reasonably believed by the attending medical expert to potentially be a hazard.
- environments include institutional settings such as hospitals and long term care facilities such as nursing homes.
- C___ difficile The risk factors and incidence of C___ difficile are known, and are described in more detail in (1) McFarland et al., "Nosocomial Acquisition of Clostridium difficile Infection", N ⁇ Enol. J. Med.. 320(4) pages 204-10 (1989); (2) Bennett et al., “£,. difficile diarrhea: A co mon-and overlooked-nursing home infection", Geriatrics. 45(9) pages 77-87 (1990); (3) Thomas et al., "Postantibiotic Colonization with Clostridium difficile in Nursing Home Patients", J. Am. Geriatr. Soc. 38, pages 415-420 (1990); and (4) Cecil Textbook of Medicine. 18th Edition. Wyngaarden and Smith editors, copyright 1988 by W.B. Saunders Company; at pages 123, 727, 757, and 1632-1633, the disclosures of all these documents being incorporated by reference herein in their entirety.
- safe and effective amount means an amount of a compound or composition high enough to significantly positively modify the infectious condition being treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment.
- the safe and effective amount of the antimicrobial agent and bismuth subsalicylate will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of other therapy, the specific antimicrobial agent employed, the particular pharmaceutically-acceptable carrier utilized, the method of administration used, and like factors within the knowledge and expertise of the attending physician. However, typical dosages of the antimicrobial agents and bismuth subsalicylate are also described hereinafter.
- the concurrent bismuth subsalicylate administration may be terminated on or before the end of about 10 days of antimicrobial treatment, but preferably it continues at least through the end of the antimicrobial treatment regimen, typically for from about 10 to about 30 days, and more preferably for about 2 to about 3 weeks.
- concurrent bismuth subsalicylate admin stration is commenced prior to, or more preferably within two days after, the start of an antimicrobial treatment regimen and continues at least until the antimicrobial treatment regimen is concluded. Most preferred is administering the bismuth subsalicylate concurrently with the entire antimicrobial treatment regimen.
- Bismuth subsalicylate is a known therapeutic agent, having been sold for many years as the active ingredient in Pepto-Bismol ® (sold by The Procter & Gamble Company).
- Preferred methods according to the present invention comprise administering from about 0.25g to about 8.5g of bismuth subsalicylate per day, preferably from about 0.5g to about 5g per day, and most preferably from about lg to about 3g per day.
- Preferred is from about 0.25g to about 1.5g per dose for from about 1 dose to about 10 doses per day; more preferred is administering from about 0.5g to about l.lg of bismuth subsalicylate per dose or from about 2 doses to about 8 doses per day; and most preferred is from about 0.5g to about l.lg of bismuth subsalicylate given per dose by 4 doses per day.
- Administration of the bismuth subsalicylate according to the present invention is by oral administration, which may be by any form, including liquids, suspensions, chewable tablets, swallowable capsules, swallowable caplets, etc.
- Preferred bismuth subsalicylate-containing compositions useful for the methods of the present invention are in liquid form comprising from about 1.75% to about 3.5% of bismuth subsalicylate.
- Such compositions typically comprise magnesium aluminum silicate (e.g., Veegum ® sold by R. T. Vanderbilt Company, Inc.), methyl salicylate, sodium salicylate, salicylic acid, and/or methyl cellulose (e.g., as present in Pepto-Bismol ® liquid and Maximum Strength Pepto-Bismol® liquid, sold by The Procter & Gamble Company).
- magnesium aluminum silicate e.g., Veegum ® sold by R. T. Vanderbilt Company, Inc.
- methyl salicylate sodium salicylate
- salicylic acid e.g., sodium salicylate, salicylic acid
- methyl cellulose e.g., as present in Pepto-Bismol ® liquid and Maximum Strength Pepto-Bismol® liquid,
- Patent 4,801,454 to Coveney, issued January 31, 1989; U.S. Patent 4,940,695, to Coveney et al., issued July 10, 1990; and U.S. Patent 5,013,560, to Stentz et al., issued May 7, 1991, the disclosures of all these patents being incorporated herein by reference in their entirety.
- Antimicrobial agents useful herein are those safe and effective for treating the infectious diseases for which the present method is useful, and which are compatible with concurrent bismuth subsalicylate administration. More preferred are those antimicrobials which are administered to treat infections other than infections of the gastrointestinal tract.
- antimicrobial agents refers to any naturally-occurring, synthetic or semi-synthetic compound or composition, or mixture thereof, which is safe for human use as used in the processes of this invention, and is effective in killing or substantially inhibiting the growth of the microorganism desired to be treated when used in the processes of this invention.
- Antibiotics are among the preferred antimicrobials useful herein.
- antibiotics can be generally classified by chemical composition, into the following principle groups: the aminoglycosides, such as gentamicin, neomycin, kanamycin, and streptomycin; the macrolides, such as erythromycin, clindamycin, and rifa pin; the penicillins, such as penicillin G, penicillin V, ampicillin and amoxycillin; the polypeptides, such as bacitracin and polymyxin; the tetracyclines, such as tetracycline, chlortetracycline, oxytetracycline, and doxycycline; the cephalosporins, such as cephalexin, cefaclor, and cephalothin; and such miscellaneous antibiotics as chloramphenicol .
- These antibiotics can be generally said to function in one of four ways: inhibition of cell wall synthesis, alteration of cell wall permeability, inhibition of protein synthesis, or inhibition of nucleic acid synthesis.
- antimicrobials useful herein include the sulfonamides; nitrofurans, such as nitrofurazone, nitrofurantoin, and furozolidone; fluoroquinolones, such as ciprofloxacin and norfloxacin; and etronidazole, tinidazole, and nimorazole.
- Antimicrobials among those useful herein are described in the following publications, incorporated by reference herein: Remington's Pharmaceutical Sciences (15th edition 1975); F. H. Meyers, et al., Review of Medical Pharmacology (7th edition 1980); Gaddum's Pharmocoloqy (8th edition 1978); and A. Goodman, A. G. Goodman and L. S.
- the tetracycl nes are preferably administered at a level of from about 100 milligrams to about 2000 milligrams, per day.
- Macrolides such as erythromycin
- Penicillins are preferably administered at a level of from about 500 milligrams to about 3000 milligrams, per day.
- the aminoglycosides (such as neomycin) are, preferably, administered at a level of from about 100 milligrams to about 8000 milligrams, per day.
- Nitrofurans are administered preferably at levels of from about 100 milligrams to about 800 milligrams, per day.
- metronidazole is administered at a level of from about 500 to about 2000 milligrams, per day.
- Antimicrobials such as tetracycline, which are known not to be compatible with bismuth subsalicylate when the two agents are dosed at about the same time, are to be administered using sound medical judgement to avoid incompatibility, and antimicrobial agents which are not suited for concurrent administration with bismuth subsalicylate are not useful according to the present invention. See, for example, CD. Ericsson, et. al., "Influence of Subsalicylate Bismuth on Absorption of Doxycycline" 247 J. of American Medical Assoc. 2266 (1982).
- Such methods include one or more of the following: staggered oral dosing of the bismuth subsalicylate and antimicrobial, through discrete administration of each compound or composition separated by at least (preferably) two hours between dosages; oral administration of the antimicrobial in an enterically coated form, i.e. coating of the antimicrobial which prevents dissolution of the antimicrobial in the stomach; and administering the antimicrobial by a non-oral route, e.g., by intraveneous or intramuscular injection.
- administration of the antimicrobial agent may be by any route as generally recognized for the particular antimicrobial being administered, the site of infection, the amount of antimicrobial agent to be administered per day, the presence of any adverse side effects, and the interaction (if any) between the antimicrobial agent and the bismuth subsalicylate. Therefore, various modes of administration include, without limitation, oral, transdermal, mucosal, sublingual, intramuscular, intravenous, intraperitoneal and subcutaneous administration, as well as topical application.
- the present invention also relates to oral antimicrobial compositions useful for treating patients at risk to ( ⁇ . difficile infection according to the present invention.
- These compositions comprise: (1) an orally administrable antimicrobial agent in an amount safe and effective for treating infections other than infections of the upper gastrointestinal tract (more preferred are those orally administrable antimicrobial agents in an amount safe and effective to be useful for treating infections other than infections of the gastrointestinal tract); (2) a safe and effective amount of bismuth subsalicylate; and (3) pharmaceutically-acceptable carrier material suitable for oral administration.
- Compositions according to the present invention may be in any form, including liquids, suspensions, capsules, tablets, chewable tablets, caplets, etc.
- pharmaceutically-acceptable carrier material means one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for oral administration to a human.
- compatible means that the components of the pharmaceutical composition are capable of being commingled with the antimicrobial agent and the bismuth subsalicylate, and with each other, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the pharmaceutical composition under ordinary use situations.
- Pharmaceutically-acceptable carrier materials must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the human subject being treated.
- substances which can serve as pharmaceutically-acceptable carrier materials are sugars such as lactose, glucose and sucrose; starches such as cornstarch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, methylcellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; stearic acid; magnesium stearate; magnesium aluminum silicate; calcium sulfate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; agar, alginic acid; and water and/or ethanol, as well as other non-toxic compatible substances used in pharmaceutical formulations.
- sugars such as lactose, glucose and sucrose
- starches such as cornstarch and potato starch
- cellulose and its derivatives such as sodium carboxy
- wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, excipients, tableting agents, stabilizers, antioxidants, and preservatives, can also be present.
- Other compatible pharmaceutical additives and actives may be included in the pharmaceutically-acceptable carrier material for use in the compositions of the present invention.
- a pharmaceutically-acceptable carrier to be used in the present composition is basically determined by the form of the composition.
- the preferred form is liquids, suspensions, capsules, tablets and the like.
- Pharmaceutically- acceptable carrier materials suitable for the preparation of dosage forms for oral administration are well-known in the art. Their selection will depend on secondary considerations like t ⁇ a e, uuj>L, s ⁇ eif stability, etc which are not critical ⁇ or tne purposes of the present invention, and can be made without difficulty by a person skilled in the art.
- the pharmaceutically-acceptable carrier materials employed in the compositions of the present invention are used at a concentration sufficient to provide a practical size to dosage relationship.
- the pharmaceutically-acceptable carrier materials in total, may comprise from about 0.1% to about 99.8% by weight of the pharmaceutical compostions of the present invention.
- the "orally administrable antimicrobial agents" useful in the present compostions are those as described in detail hereinbefore which are safe and effective when administered orally for treating the identified infection.
- the antimicrobial agent may comprise from about 0.1% to about 99.8% by weight of the antimicrobial composition of the present invention, typically from about 1 mg to about 2g per dose safe and effective for treating infections other than infections of the upper gastrointestinal tract.
- the bismuth subsalicylate may comprise from about 0.1% to about 99.8% by weight of the antimicrobial composition of the present invention, typically from about 0.25g to about 1.5g per dose.
- Exa ole An elderly nursing home patient suffering from a respiratory tract infection and in a facility know to further increase this patient's risk to C... difficile infection is treated as follows. Ten days of orally administered amoxycillin (500 mg; three times per day) and concurrently for the same 10 days, and continuing thereafter for a total of 3 weeks, orally administered bismuth subsalicylate (525 mg; four times per day; Pepto-Bismol ® liquid, sold by The Procter & Gamble Company). The course of treatment is completed with resolution of the infection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Procédés de traitement de patients soumis à des infections provoquées par des agents antimicrobiens, dans le cas d'un risque d'infection par C. difficile, comprenant l'administration orale simultanée effectuée avant le terme d'une durée de 5 jours environ de thérapie antimicrobienne, d'une quantité efficace de sous-salicylate de bismuth.Methods of treating patients subjected to infections caused by antimicrobial agents, in the case of a risk of C. difficile infection, comprising simultaneous oral administration carried out before the end of a duration of approximately 5 days of therapy antimicrobial, an effective amount of bismuth subsalicylate.
Description
ANTIMICROBIAL TREATMENT METHODS AND COMPOSITIONS
BACKGROUND OF THE INVENTION The present invention relates to a method for treating patients having infections with antimicrobials when the patients are at risk to Clostridium difficile ("L. difficile", infection. This method comprises concurrently orally administering before the end of about 5 days of antimicrobial therapy a safe and effective amount of bismuth subsalicylate. The present invention also relates to compositions useful for the method of the present invention comprising certain antimicrobials and bismuth subsalicylate.
"A commonly recognized complication of antibiotic therapy is diarrhea and/or pseudome branous colitis. This is due to bowel overgrowth by difficile, which elaborates an exotoxin that is responsible for symptoms. Discontinuation of antibiotic therapy will usually lead to resolution of treatment, but some patients require vancomycin or metronidazole." (Cecil Textbook of Medicine. 18th Edition. Wyngaarden and Smith editors, copyright 1988 by W.B. Saunders Company; at page 123.)
Reports have discussed the prevalence of C difficile in hospitals [McFarland et al., "Nosoco ial Acquisition of Clostridium difficile Infection", N. Enol . J. Med.. 320(4) pages 204-10 (1989)] and in nursing homes [Bennett et al., "C. difficile diarrhea: A common - and overlooked - nursing home infection", Geriatrics. 45(9) pages 77-87 (1990)]. A relationship has been observed between nursing home patients with C^ difficile following antibiotic treatment and high mortality rate. [Bender et al., "Is Clostridium difficile Endemic in Chronic-Care Facilities?", The Lancet. July 5, 1986, pp 11-13; Thomas et al., "Postantibiotic Colonization with Clostridium difficile in Nursing Home Patients", J. Am. Geriatr. Soc. 38. pages 415-420 (1990).] This research concluded that postantibiotic (____. difficile infection correlates with increased death rate separate from the risk of antibiotic treatment alone. Other research relating to C^ difficile infection includes: ilkins, "Role of Clostridium difficile Toxins in Disease", Gastroenterologv. 93 (2), pp. 389-391 (1987);
Kyooit et al., "Protein-Losing Enteropathy Associated with Clostridium difficile Infection", The Lancet. June 17, 1989, pp. 1353-1355; Bennett et al., "Evaluation of a Latex Agglutination Test for Clostridium difficile in Two Nursing Home Outbreaks", jL. Clin. Microbial, 27 (5), pp. 889-893 (1989).
"The most important therapeutic decision with antibiotic-associated diarrhea or colitis is discontinuation of the implicated agent. This often results in resolution of symptoms with no necessity for further diagnostic tests or therapy. Patients with severe or persistent symptoms should undergo endoscopy to define anatomic changes and stool examination to detect j_ difficile cytotoxin." (Cecil Textbook of Medicine. supra, at page 1632). Specific therapies for £___. difficile infection include cholestyra ine to bind the toxin or antimicrobials (such as metronidazole or preferably vancomycin) to inhibit the pathogen.
Bismuth subsalicylate has been investigated for its effectiveness in treating C_j. difficile colitis in hamsters [Chang et al., "Effect of Bismuth Subsalicylate on Clostridium difficile Colitis in Hamsters", Rev. Infect. Pis.. 12 (Supplement 1), pages S57-S58 (1990)]. Further, bismuth subsalicylate has been used to treat (_____ difficile diarrhea in nursing homes (Bennett et al., Geriatrics, supra) and chronic diarrhea due to C difficile in children (Gryboski et al., "Effect of bismuth subsalicylate on chronic diarrhea in childhood: a preliminary report", Rev. Infect. Pis.. \2 (Supplement 1), pages S36-S40 (1990)].
Clearly, there is a need for treatment methods which improve the safety and/or effectiveness of antimicrobial treatment for patients at risk to ]____. difficile infection. It has been surprisingly discovered by the present invention that when bismuth subsalicylate therapy is concurrently administered with a course of antimicrobial therapy, there is a significant reduction in the death rate of this patient population versus similar patients receiving only antimicrobial therapy. Further, because the deaths associated with antimicrobial treatment alone can occur very suddenly and within about 5 days after the start of the treatment regimen, it is also important for
xne purposes and the present method to concurrently orally administer the bismuth subsalicylate before the end of about 5 days of antimicrobial treatment.
Thus, an object of the present invention is to provide compositions and methods for treating patients at risk to Cj. difficile infection with antimicrobials. A further objective is to improve the chances of successful completion of an antimicrobial treatment regimen in patients at risk to C^. difficile infection. A further object is to reduce the mortality rate for patients being treated with antimicrobials who are at risk to ______ difficile infection.
These and other objects of the present invention will become readily apparent from the detailed description which follows.
All percentages and ratios used herein are by weight, and all measurements made at 25*C, unless otherwise specified.
SUMMARY OF THE INVENTION The present invention relates to a method for treating with antimicrobials patients at risk to £__. difficile infection, said method comprising administering to a patient at risk to £__. difficile infection who needs antimicrobial treatment for infection a safe and effective amount of an antimicrobial agent and concurrently orally administering before the end of about 5 days of antimicrobial treatment a safe and effective amount of bismuth subsalicylate. The present invention also relates to oral antimicrobial compositions useful for treating patients at risk to Z difficile infection comprising: (a) an orally administrable antimicrobial agent in an amount safe and effective for treating infections other than infections of the upper gastrointestinal tract; (b) a safe and effective amount of bismuth subsalicylate; and (c) pharmaceutically-acceptable carrier material suitable for oral administration.
DETAILED PESCRIPTION OF THE INVENTION Antimicrobial Treatment Methods: The present invention relates to a method for treating with antimicrobials patients at risk to £__. difficile infection who need antimicrobial treatment for infection. This method comprises
administering to such patients a safe and effective amount of an antimicrobial agent and concurrently orally administering before the end of about 5 days of antimicrobial treatment a safe and effective amount of bismuth subsalicylate. The present invention methods are useful for treating with antimicrobial agents infections of humans. Such infections are typically other than infections of the upper gastrointestinal tract (e.g., Helicobacter pylori, a.k.a. Campy!obacter pyloridis. infection of the stomach which results in gastritis and ulcers as taught for example by European Patent Application Publication Number 206,625 published December 30, 1986 by Marshall), and preferably the present invention involves treating infections not involving gastrointestinal tract infection. Examples of infections treatable according to the present invention include, but are not limited to, upper and lower respiratory tract infections, sepsis, and wound infections including surgical wound infections.
The term "patient at risk to C^. difficile infection", as used herein, means a human subject in need of antimicrobial treatment for infection and this subject is either infected with £__. difficile or deemed to be at risk to becoming infected with C difficile within the scope of sound medical judgment. Patients at risk to £__. difficile infection therefore include patients already diagnosed as being colonized by C__. difficile (but preferably not exhibiting £___ difficile diarrhea), as well as those patients in an environment wherein C^ difficile infection is known to be present or is reasonably believed by the attending medical expert to potentially be a hazard. Such environments include institutional settings such as hospitals and long term care facilities such as nursing homes. The risk factors and incidence of C___ difficile are known, and are described in more detail in (1) McFarland et al., "Nosocomial Acquisition of Clostridium difficile Infection", N^ Enol. J. Med.. 320(4) pages 204-10 (1989); (2) Bennett et al., "£,. difficile diarrhea: A co mon-and overlooked-nursing home infection", Geriatrics. 45(9) pages 77-87 (1990); (3) Thomas et al., "Postantibiotic Colonization with Clostridium difficile in Nursing Home Patients", J. Am. Geriatr. Soc. 38, pages 415-420
(1990); and (4) Cecil Textbook of Medicine. 18th Edition. Wyngaarden and Smith editors, copyright 1988 by W.B. Saunders Company; at pages 123, 727, 757, and 1632-1633, the disclosures of all these documents being incorporated by reference herein in their entirety.
The term "safe and effective amount", as used herein, means an amount of a compound or composition high enough to significantly positively modify the infectious condition being treated, but low enough to avoid serious side effects (at a reasonable benefit/risk ratio), within the scope of sound medical judgment. The safe and effective amount of the antimicrobial agent and bismuth subsalicylate will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of other therapy, the specific antimicrobial agent employed, the particular pharmaceutically-acceptable carrier utilized, the method of administration used, and like factors within the knowledge and expertise of the attending physician. However, typical dosages of the antimicrobial agents and bismuth subsalicylate are also described hereinafter.
The terms "concurrently" and "concurrent", as used herein, mean that the safe and effective amount of bismuth subsalicylate is orally administered within 24 hours of administration of the antimicrobial agent. As noted hereinbefore, this concurrent administration of the bismuth subsalicylate should occur or commence before the end of about 5 days of antimicrobial treatment. Bismuth subsalicylate administration may therefore begin before commencement of the antimicrobial treatment, at the same time, or even after commencement of the antimicrobial treatment but before about 5 days of antimicrobial treatment have been completed. Further, the concurrent bismuth subsalicylate administration may be terminated on or before the end of about 10 days of antimicrobial treatment, but preferably it continues at least through the end of the antimicrobial treatment regimen, typically for from about 10 to about 30 days, and more preferably for about 2 to about 3 weeks.
Preferably, concurrent bismuth subsalicylate admin stration is commenced prior to, or more preferably within two days after, the start of an antimicrobial treatment regimen and continues at least until the antimicrobial treatment regimen is concluded. Most preferred is administering the bismuth subsalicylate concurrently with the entire antimicrobial treatment regimen.
Bismuth subsalicylate is a known therapeutic agent, having been sold for many years as the active ingredient in Pepto-Bismol® (sold by The Procter & Gamble Company). Preferred methods according to the present invention comprise administering from about 0.25g to about 8.5g of bismuth subsalicylate per day, preferably from about 0.5g to about 5g per day, and most preferably from about lg to about 3g per day. Preferred is from about 0.25g to about 1.5g per dose for from about 1 dose to about 10 doses per day; more preferred is administering from about 0.5g to about l.lg of bismuth subsalicylate per dose or from about 2 doses to about 8 doses per day; and most preferred is from about 0.5g to about l.lg of bismuth subsalicylate given per dose by 4 doses per day. Administration of the bismuth subsalicylate according to the present invention is by oral administration, which may be by any form, including liquids, suspensions, chewable tablets, swallowable capsules, swallowable caplets, etc. Preferred bismuth subsalicylate-containing compositions useful for the methods of the present invention are in liquid form comprising from about 1.75% to about 3.5% of bismuth subsalicylate. Such compositions typically comprise magnesium aluminum silicate (e.g., Veegum® sold by R. T. Vanderbilt Company, Inc.), methyl salicylate, sodium salicylate, salicylic acid, and/or methyl cellulose (e.g., as present in Pepto-Bismol® liquid and Maximum Strength Pepto-Bismol® liquid, sold by The Procter & Gamble Company). Bismuth subsalicylate-containing pharmaceutical compositions and their method of preparation are also described in detail in U.S. Patent 4,801,454, to Coveney, issued January 31, 1989; U.S. Patent 4,940,695, to Coveney et al., issued July 10, 1990; and U.S. Patent 5,013,560, to Stentz et al., issued May 7, 1991, the
disclosures of all these patents being incorporated herein by reference in their entirety.
Antimicrobial agents useful herein are those safe and effective for treating the infectious diseases for which the present method is useful, and which are compatible with concurrent bismuth subsalicylate administration. More preferred are those antimicrobials which are administered to treat infections other than infections of the gastrointestinal tract.
A wide variety of antimicrobial agents are therefore useful in this invention. The term "antimicrobial agents", as used herein, refers to any naturally-occurring, synthetic or semi-synthetic compound or composition, or mixture thereof, which is safe for human use as used in the processes of this invention, and is effective in killing or substantially inhibiting the growth of the microorganism desired to be treated when used in the processes of this invention. Antibiotics are among the preferred antimicrobials useful herein. Such antibiotics can be generally classified by chemical composition, into the following principle groups: the aminoglycosides, such as gentamicin, neomycin, kanamycin, and streptomycin; the macrolides, such as erythromycin, clindamycin, and rifa pin; the penicillins, such as penicillin G, penicillin V, ampicillin and amoxycillin; the polypeptides, such as bacitracin and polymyxin; the tetracyclines, such as tetracycline, chlortetracycline, oxytetracycline, and doxycycline; the cephalosporins, such as cephalexin, cefaclor, and cephalothin; and such miscellaneous antibiotics as chloramphenicol . These antibiotics can be generally said to function in one of four ways: inhibition of cell wall synthesis, alteration of cell wall permeability, inhibition of protein synthesis, or inhibition of nucleic acid synthesis.
Other antimicrobials useful herein include the sulfonamides; nitrofurans, such as nitrofurazone, nitrofurantoin, and furozolidone; fluoroquinolones, such as ciprofloxacin and norfloxacin; and etronidazole, tinidazole, and nimorazole. Antimicrobials among those useful herein are described in the following publications, incorporated by reference herein: Remington's Pharmaceutical Sciences (15th edition 1975); F. H.
Meyers, et al., Review of Medical Pharmacology (7th edition 1980); Gaddum's Pharmocoloqy (8th edition 1978); and A. Goodman, A. G. Goodman and L. S. Gilman, The Pharmacological Basis of Therapeutics (6th edition 1980). While any of these antimicrobials may be used, penicillin, erythromycin, doxycycline, metronidazole, tinidazole, clindamycin, amoxycillin, ampicillin, cefaclor, ciprofloxacin, norfloxacin, and nitrofurantoin are among the preferred antimicrobials for use in the present invention. As stated above, the specific preferred quantity of antimicrobial, and duration of treatment used in the methods of this invention will, in addition to other factors, depend upon the particular antimicrobial used and its pharmacology. In general, though, the tetracycl nes are preferably administered at a level of from about 100 milligrams to about 2000 milligrams, per day. Macrolides (such as erythromycin) are preferably administered at a level of from about 1000 milligrams to about 4000 milligrams, per day. Penicillins are preferably administered at a level of from about 500 milligrams to about 3000 milligrams, per day. The aminoglycosides (such as neomycin) are, preferably, administered at a level of from about 100 milligrams to about 8000 milligrams, per day. Nitrofurans (such as nitrofurantoin) are administered preferably at levels of from about 100 milligrams to about 800 milligrams, per day. Preferably, metronidazole is administered at a level of from about 500 to about 2000 milligrams, per day.
Antimicrobials, such as tetracycline, which are known not to be compatible with bismuth subsalicylate when the two agents are dosed at about the same time, are to be administered using sound medical judgement to avoid incompatibility, and antimicrobial agents which are not suited for concurrent administration with bismuth subsalicylate are not useful according to the present invention. See, for example, CD. Ericsson, et. al., "Influence of Subsalicylate Bismuth on Absorption of Doxycycline" 247 J. of American Medical Assoc. 2266 (1982). Hence, it is preferred to administer those antimicrobials that are subject to adverse interaction with bismuth subsalicylate by methods that minimize such interactions, i.e., by minimizing the simultaneous presence
or antimicrobial and bismuth subsalicylate in the stomach. Such methods include one or more of the following: staggered oral dosing of the bismuth subsalicylate and antimicrobial, through discrete administration of each compound or composition separated by at least (preferably) two hours between dosages; oral administration of the antimicrobial in an enterically coated form, i.e. coating of the antimicrobial which prevents dissolution of the antimicrobial in the stomach; and administering the antimicrobial by a non-oral route, e.g., by intraveneous or intramuscular injection.
When treating the identified infection, administration of the antimicrobial agent may be by any route as generally recognized for the particular antimicrobial being administered, the site of infection, the amount of antimicrobial agent to be administered per day, the presence of any adverse side effects, and the interaction (if any) between the antimicrobial agent and the bismuth subsalicylate. Therefore, various modes of administration include, without limitation, oral, transdermal, mucosal, sublingual, intramuscular, intravenous, intraperitoneal and subcutaneous administration, as well as topical application. Antimicrobial Compositions:
The present invention also relates to oral antimicrobial compositions useful for treating patients at risk to (λ. difficile infection according to the present invention. These compositions comprise: (1) an orally administrable antimicrobial agent in an amount safe and effective for treating infections other than infections of the upper gastrointestinal tract (more preferred are those orally administrable antimicrobial agents in an amount safe and effective to be useful for treating infections other than infections of the gastrointestinal tract); (2) a safe and effective amount of bismuth subsalicylate; and (3) pharmaceutically-acceptable carrier material suitable for oral administration. Compositions according to the present invention may be in any form, including liquids, suspensions, capsules, tablets, chewable tablets, caplets, etc.
The term "pharmaceutically-acceptable carrier material", as used herein, means one or more compatible solid or liquid filler
diluents or encapsulating substances which are suitable for oral administration to a human. The term "compatible", as used herein, means that the components of the pharmaceutical composition are capable of being commingled with the antimicrobial agent and the bismuth subsalicylate, and with each other, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the pharmaceutical composition under ordinary use situations. Pharmaceutically-acceptable carrier materials must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the human subject being treated.
Some examples of substances which can serve as pharmaceutically-acceptable carrier materials are sugars such as lactose, glucose and sucrose; starches such as cornstarch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, methylcellulose, cellulose acetate; powdered tragacanth; malt; gelatin; talc; stearic acid; magnesium stearate; magnesium aluminum silicate; calcium sulfate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and oil of theobroma; polyols such as propylene glycol, glycerine, sorbitol, mannitol, and polyethylene glycol; agar, alginic acid; and water and/or ethanol, as well as other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents and lubricants such as sodium lauryl sulfate, as well as coloring agents, flavoring agents, excipients, tableting agents, stabilizers, antioxidants, and preservatives, can also be present. Other compatible pharmaceutical additives and actives may be included in the pharmaceutically-acceptable carrier material for use in the compositions of the present invention.
The choice of a pharmaceutically-acceptable carrier to be used in the present composition is basically determined by the form of the composition. The preferred form is liquids, suspensions, capsules, tablets and the like. Pharmaceutically- acceptable carrier materials suitable for the preparation of dosage forms for oral administration are well-known in the art. Their selection will depend on secondary considerations like
tαa e, uuj>L, sπeif stability, etc which are not critical τor tne purposes of the present invention, and can be made without difficulty by a person skilled in the art.
The pharmaceutically-acceptable carrier materials employed in the compositions of the present invention are used at a concentration sufficient to provide a practical size to dosage relationship. The pharmaceutically-acceptable carrier materials, in total, may comprise from about 0.1% to about 99.8% by weight of the pharmaceutical compostions of the present invention. The "orally administrable antimicrobial agents" useful in the present compostions are those as described in detail hereinbefore which are safe and effective when administered orally for treating the identified infection. The antimicrobial agent may comprise from about 0.1% to about 99.8% by weight of the antimicrobial composition of the present invention, typically from about 1 mg to about 2g per dose safe and effective for treating infections other than infections of the upper gastrointestinal tract. Also, the bismuth subsalicylate may comprise from about 0.1% to about 99.8% by weight of the antimicrobial composition of the present invention, typically from about 0.25g to about 1.5g per dose.
The following example further describes and demonstrates an embodiment within the scope of the present invention. The example is given solely for the purpose of illustration, and is not to be construed as limitations of the present invention since many variations thereof are possible without departing from its spirit and scope.
Exa ole An elderly nursing home patient suffering from a respiratory tract infection and in a facility know to further increase this patient's risk to C... difficile infection is treated as follows. Ten days of orally administered amoxycillin (500 mg; three times per day) and concurrently for the same 10 days, and continuing thereafter for a total of 3 weeks, orally administered bismuth subsalicylate (525 mg; four times per day; Pepto-Bismol® liquid, sold by The Procter & Gamble Company). The course of treatment is completed with resolution of the infection.
Claims
1. The use of bismuth subsalicylate for the manufacture of a medica¬ ment for the treatment with antimicrobials of patients at risk to C. difficile infection, said treatment comprising administering to a patient at risk to C. difficile infection who needs antimi¬ crobial treatment for infection a safe and effective amount of an antimicrobial agent and concurrently orally administering before the end of 5 days of antimicrobial treatment a safe and effective amount of bismuth subsalicylate.
2. The use of bismuth subsalicylate for the manufacture of a medica¬ ment for the treatment with antimicrobials of patients at risk to C. difficile infection, said treatment comprising administering to a patient at risk to C. difficile infection, in order to treat an infection other than an infection of the gastrointestinal tract, a safe and effective amount of an antimicrobial agent and concurrently orally administering before the end of 5 days of antimicrobial treatment a safe and effective amount of bismuth subsalicylate.
3. The use of bismuth subsa icylate according to Claim 1 or 2 wherein the bismuth subsalicylate is administered concurrently within two days after the start of the antimicrobial treatment.
L The use of bismuth subsalicylate according to any of Claims 1-3 wherein the bismuth subsalicylate is administered concurrently at least until the antimicrobial treatment is concluded.
i. The use of bismuth subsalicylate according to any of Claims 1-4 wherein the antimicrobial agent is selected from the group consisting of aminoglycosides, macrolides, penicillins, polypep- tides, tetracyclines, cephalosporins, chloramphenicol, sulfona- ides, nitrofurans, fl oroquinolones, metronidazole, tinidazole, nimorazole, and mixtures thereof.
6. The use of bismuth subsalicylate according to any of Claims 1-5 wherein the antimicrobial agent is selected from penicillin, erythromycin, doxycycline, metronidazole, tinidazole, clinda¬ mycin, amoxycillin, ampicillin, cefaclor, ciprofloxacin, norflox¬ acin, nitrofurantoin, and mixtures thereof.
7. The use of bismuth subsalicylate according to any of Claims 1-6 wherein the bismuth subsalicylate is administered in an amount of from 0.25g to 8.5g per day, for from 10 to 30 days.
8. The use of bismuth subsalicylate according to any of Claims 1-7 wherein the bismuth subsalicylate is administered for from 2 to 3 weeks.
9. An oral antimicrobial composition comprising:
(a) an orally administrable antimicrobial agent in an amount safe and effective for treating infections other than infections of the upper gastrointestinal tract;
(b) a safe and effective amount of bismuth subsalicylate; and
(c) pharmaceutically-acceptable carrier material suitable for oral administration.
10. The oral antimicrobial composition according to Claim 9 com¬ prising from 0.25g to 1.5g of bismuth subsalicylate per dose.
11. The oral antimicrobial composition according to Claim 9 or 10 in unit dose form.
12. A method for treating with antimicrobials patients at risk to C. difficile infection, said method comprising administering to a patient at risk to C. difficile infection who needs antimicrobial treatment for infection a safe and effective amount of an antimicrobial agent and concurrently orally administering before the end of about 5 days of antimicrobial treatment a safe and effective amount of bismuth subsalicylate.
13. The method according to Claim 12 wherein the bismuth subsalicylate is administered concurrently within two days after the start of the antimicrobial treatment.
14. The method according to Claim 13 wherein the bismuth subsalicylate is administered concurrently at least until the antimicrobial treatment is concluded.
15. The method according to Claim 12 wherein the antimicrobial agent is selected from the group consisting of aminoglycosides, macrolides, penicillins, polypeptides, tetracyclines, cephalosporins, chloramphenicol , sulfonamides, nitrofurans, fluoroquinolones, metronidazole, tinidazole, nimorazole, and mixtures thereof.
16. The method according to Claim 15 wherein the antimicrobial agent is selected from penicillin, erythromycin, doxycycline, metronidazole, tinidazole, clindamycin, amoxycillin, ampicillin, cefaclor, ciprofloxacin, norfloxacin, nitrofurantoin, and mixtures thereof.
17. The method according to Claim 13 wherein the bismuth subsalicylate is administered in an amount of from about 0.25g to about 8.5g per day, for from about 10 to about 30 days.
18. The method according to Claim 15 wherein the bismuth subsalicylate is administered in an amount of from about 0.5g to about 5g per day.
19. A method for treating with antimicrobials patients at risk to C. difficile infection, said method comprising administering to a patient at risk to C. difficile infection, in order to treat an infection other than an infection of the gastrointestinal tract, a safe and effective amount of an antimicrobial agent and concurrently orally administering before the end of about 5 days of antimicrobial treatment a safe and effective amount of bismuth subsalicylate.
20. The method according to Claim 19 wherein the antimicrobial agent is selected from the group consisting of aminoglycosides, macrolides, penicillins, polypeptides, tetracyclines, cephalosporins, chloramphenicol , sulfonamides, nitrofurans, fluoroquinolones, metronidazole, tinidazole, nimorazole, and mixtures thereof.,
21. The method according to Claim 19 wherein the bismuth subsalicylate is administered concurrently within 2 days after the start of the antimicrobial treatment in an amount of from about 0.25g to about 8.5g per day.
22. The method according to Claim 21 wherein the bismuth subsalicylate is administered concurrently at least until the antimicrobial treatment is concluded.
23. The method according to Claim 22 wherein the antimicrobial agent is selected from the group consisting of penicillin, erythromycin, doxycycline, metronidazole, tinidazole, clindamycin, amoxycillin, ampicillin, cefaclor, ciprofloxacin, norfloxacin, nitrofurantoin, and mixtures thereof.
24. The method according to Claim 19 wherein the patient being treated is selected from patients having upper respiratory tract infections, lower respiratory tract infections, sepsis, or wound infections, and the antimicrobial agent is administered in an amount safe and effective for treating one or more of these infections.
25. The method according to Claim 21 wherein the bismuth subsalicylate is administered for from about 2 to about 3 weeks.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73540091A | 1991-07-24 | 1991-07-24 | |
| US735400 | 1991-07-24 | ||
| PCT/US1992/005848 WO1993001818A1 (en) | 1991-07-24 | 1992-07-15 | Antimicrobial treatment methods and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0595890A1 true EP0595890A1 (en) | 1994-05-11 |
Family
ID=24955626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP92915528A Withdrawn EP0595890A1 (en) | 1991-07-24 | 1992-07-15 | Antimicrobial treatment methods and compositions |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0595890A1 (en) |
| JP (1) | JPH06509340A (en) |
| AU (1) | AU2324392A (en) |
| BR (1) | BR9206300A (en) |
| CA (1) | CA2113614A1 (en) |
| IE (1) | IE922403A1 (en) |
| MA (1) | MA22597A1 (en) |
| MX (1) | MX9204338A (en) |
| PT (1) | PT100729A (en) |
| WO (1) | WO1993001818A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN771596A0 (en) | 1996-01-25 | 1996-02-15 | Mclean, Allan Joseph | Methods of and compositions for potentiating the action of agents active on cell-wall sites of susceptible bacteria |
| DE10236347A1 (en) † | 2002-08-08 | 2004-02-19 | Basf Coatings Ag | Electrodip paints, useful for coating electrically conductive materials, in preparation of electrodip coated components and/or in multilayer wet-on-wet painting, contain bismuth compounds and binder |
| WO2005014567A1 (en) * | 2003-08-12 | 2005-02-17 | Biocon Limited | Mycophenolic acid bismuth salt |
| US20170319603A1 (en) * | 2016-03-24 | 2017-11-09 | Paratek Pharmaceuticals, Inc. | Methods for treating and preventing c. difficile infection |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3650787T2 (en) * | 1985-06-13 | 2006-11-16 | Dr. Barry James Marshall | A pharmaceutical composition for the treatment of gastrointestinal disorders containing bismuth and an antimicrobial agent |
| JP2733849B2 (en) * | 1987-10-12 | 1998-03-30 | ボロディー，ソーマス・ユリウス | Improved method for treating gastrointestinal disorders |
-
1992
- 1992-07-15 EP EP92915528A patent/EP0595890A1/en not_active Withdrawn
- 1992-07-15 CA CA002113614A patent/CA2113614A1/en not_active Abandoned
- 1992-07-15 JP JP5502889A patent/JPH06509340A/en active Pending
- 1992-07-15 AU AU23243/92A patent/AU2324392A/en not_active Abandoned
- 1992-07-15 BR BR9206300A patent/BR9206300A/en not_active Application Discontinuation
- 1992-07-15 WO PCT/US1992/005848 patent/WO1993001818A1/en not_active Application Discontinuation
- 1992-07-21 MA MA22884A patent/MA22597A1/en unknown
- 1992-07-23 MX MX9204338A patent/MX9204338A/en unknown
- 1992-07-23 IE IE240392A patent/IE922403A1/en not_active Application Discontinuation
- 1992-07-24 PT PT100729A patent/PT100729A/en not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9301818A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX9204338A (en) | 1993-03-01 |
| IE922403A1 (en) | 1993-01-27 |
| WO1993001818A1 (en) | 1993-02-04 |
| MA22597A1 (en) | 1993-04-01 |
| CA2113614A1 (en) | 1993-02-04 |
| JPH06509340A (en) | 1994-10-20 |
| PT100729A (en) | 1993-10-29 |
| BR9206300A (en) | 1994-08-02 |
| AU2324392A (en) | 1993-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barlow | Nalidixic acid in infections of urinary tract | |
| JP6101010B2 (en) | Treatment of diseases associated with the use of antibiotics | |
| KR100257367B1 (en) | Medicaments for treating gastrointestinal disorders | |
| RO115780B1 (en) | SINERGICA COMBINATION | |
| DK2337575T3 (en) | A method of treatment with single doses of oritavancin | |
| Keusch et al. | Summary of a workshop on clindamycin colitis | |
| Tremblay et al. | Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses | |
| Savage et al. | Nosocomial spread of Clostridium difficile | |
| Cunha | Nitrofurantoin—current concepts | |
| EP0595890A1 (en) | Antimicrobial treatment methods and compositions | |
| Eykyn | Staphylococcal bacteraemia and endocarditis and fusidic acid | |
| US3949077A (en) | Synergistic antibiotic compositions | |
| Faro | New considerations in treatment of urinary tract infections in adults | |
| Schneider et al. | Evaluation of an oral prolonged-release antibiotic formulation | |
| Okumura et al. | Infective endocarditis caused by highly penicillin-resistant Streptococcus pneumoniae: successful treatment with cefuzonam, ampicillin and imipenem | |
| Sharma et al. | Cefuroxime axetil: An oral prodrug of cefuroxime sodium | |
| Brumfitt et al. | Pivmecillinam in complicated urinary infections failing to respond to conventional therapy | |
| Gurwith et al. | Prospective comparison of cefoxitin and cefazolin in infections caused by aerobic bacteria | |
| Sullivan et al. | Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam | |
| Fu et al. | Synergistic activity of apalcillin and gentamicin in a combination therapy in experimental Pseudomonas bacteraemia of neutropenic mice | |
| Pezzani | Cefuroxime | |
| Flood | Gastrointestinal complications of antibiotic therapy | |
| Millard | Further experience with augmentin in the treatment of skin infections | |
| AM | NALIDIXIC ACID IN INFECTIONS OF URINARY TRACT. LABORATORY AND CLINICAL INVESTIGATIONS. | |
| Paterson et al. | 21 Cefaclor, Cefprozil, and Loracarbef |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19940112 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
| 17Q | First examination report despatched |
Effective date: 19951218 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19970828 |